Biology of Platelet Factor 4

Summary

Principal Investigator: Abd Al Roof Higazi
Abstract: Platelets contain a unique chemokine Platelet Factor 4 (PF4), which is released in large amounts at sites of platelet activation. While a number of potential roles of PF4 in the cardiovascular system have been suggested based on in vitro data, its in vivo biological role(s) is unclear. In this application we will define the role of PF4 in platelet biology, extending our preliminary in vitro data of PF4's interaction with low-density lipoprotein (LDL), with its receptor LDL-R and with the related receptor LRP. We will also extend these observations in vivo. Specific aims include: Number 1: Characterize PF4's interactions with LDL-R and LRP in vitro. These studies will characterize the interactions of PF4 with LDL binding to the LDL-receptor (R), identifying the responsible domains within PF4 and LDL-R using defined chimeras and mutants, and exploring the hypothesis that oligomerization of PF4 by cellular proteoglycans frustrates the endocytosis of LDL/LDL-R complexes. We will also examine the specificity of PF4's interactions with LRP and further characterize its ability to influence the uptake of urokinase into cells. Number 2: Effect of PF4 on the development of atherosclerosis focusing on a transgenic mice approach. We have created PF4 null mice (mPF4) and mice overexpressing human PF4 (hPF4+). These animals will be studied to see the effect of PF4 level on LDL metabolism. The animals will also be crossed onto several well-defined atherogenic models that will test specific issues related to PF4's affect on LDL metabolism and the development of atherosclerosis. Number 3: Effect of PF4 on the cardiovascular biology focusing on a transgenic mice approach. Strong in vitro data developed by our group and others have suggested a role of PF4 in the development of thrombosis, angiogenesis and megakaryopoiesis. However, a physiologic role of PF4 in these processes has yet to be demonstrated. In this specific aim, we plan to use the mPF4-/- and hPF4+ mice to begin to define the biological relevance of the in vitro studies in the literature and presented in the 1st specific aim. Crosses onto other transgenic animal models that will enhance our understanding of the molecular mechanism(s) by which PF4 contributes to these biological processes are also proposed. We believe that new information derived by this application will have clinical relevance. The biological studies of PF4 should provide new insights into the regulation of several cardiovascular-related processes, and may offer novel approaches for the treatment of cardiovascular diseases.
Funding Period: 2002-08-01 - 2007-07-31
more information: NIH RePORT

Top Publications

  1. ncbi Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia
    Lubica Rauova
    Division of Hematology, Children s Hospital of Philadelphia, PA, USA
    Blood 105:131-8. 2005
  2. pmc Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner
    Guangyao Yu
    University of Pennsylvania, 207 John Morgan, Philadelphia, PA 19104, USA
    Blood 105:3545-51. 2005
  3. pmc Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications
    Lubica Rauova
    Department of Pediatrics, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Blood 107:2346-53. 2006
  4. ncbi alpha-Defensin: link between inflammation and atherosclerosis
    Hisham Nassar
    Department of Cardiology, Hadassah Medical Center, Jerusalem, IL 91120, Israel
    Atherosclerosis 194:452-7. 2007
  5. ncbi Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE-/- mice
    Bruce S Sachais
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Thromb Haemost 98:1108-13. 2007

Scientific Experts

  • BRUCE SACHAIS
  • Lubica Rauova
  • Hisham Nassar
  • Khalil Bdeir
  • Mortimer Poncz
  • Douglas B Cines
  • Guangyao Yu
  • Sa ed Akkawi
  • Ehud Lavi
  • John Tomaszewski
  • P N Raghunath
  • Samuel N Heyman
  • Abd Al Roof Higazi
  • M Anna Kowalska
  • Li Zhai
  • Gowthami M Arepally
  • Steven E McKenzie
  • Michael P Reilly
  • Peihong Ma
  • Chandrasekaran Nagaswami
  • Gowthami Arepally
  • John W Weisel
  • Ann H Rux

Detail Information

Publications5

  1. ncbi Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia
    Lubica Rauova
    Division of Hematology, Children s Hospital of Philadelphia, PA, USA
    Blood 105:131-8. 2005
    ....
  2. pmc Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner
    Guangyao Yu
    University of Pennsylvania, 207 John Morgan, Philadelphia, PA 19104, USA
    Blood 105:3545-51. 2005
    ..These results demonstrate that PF4 is able to increase expression of E-selectin by endothelial cells and represents another potential mechanism by which platelets may participate in atherosclerotic lesion progression...
  3. pmc Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications
    Lubica Rauova
    Department of Pediatrics, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Blood 107:2346-53. 2006
    ..We believe that this focus on surface PF4 advances our understanding of the pathogenesis of HIT, suggests ways to identify patients at high risk to develop HIT upon heparin exposure, and offers new therapeutic strategies...
  4. ncbi alpha-Defensin: link between inflammation and atherosclerosis
    Hisham Nassar
    Department of Cardiology, Hadassah Medical Center, Jerusalem, IL 91120, Israel
    Atherosclerosis 194:452-7. 2007
    ..We asked, therefore, if alpha-defensins are risk factors for the presence and severity of atherosclerosis...
  5. ncbi Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE-/- mice
    Bruce S Sachais
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Thromb Haemost 98:1108-13. 2007
    ..These data demonstrate, for the first time, that the platelet specific chemokine PF4 promotes atherosclerotic lesion development in vivo...